Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial

作者：Huabin Hu, Xutao Shen, Yunfeng Li, Jiaming Zhou, Ping Liu, Jianwei Zhang, Yujie Hou, XiaoZhong Wang, Jiaye Deng, Zhuoxin Zheng, J Y Li, Ping Lan, Xiaojian Wu, Liang Kang, Meijin Huang, Zhen He, Xiaosheng He, Zuli Yang, Liang Huang, Hui Wang, Huaiming Wang, Shuangling Luo, Dianke Chen, Xiaoyu Xie, Yan Zhang, Xiaohui Zhai, Shanshan Li, Weiwei Li, Jiancong Hu, Tao Yang, Chao Wang, Weihao Deng, Yan Huang, Wuteng Cao, Fangqian Li, Lishuo Shi, Li Ling, Yanhong Deng · 发表于：The Lancet Oncology · 年份：2026 · DOI：10.1016/s1470-2045(26)00220-2 · 研究领域：Genetic factors in colorectal cancer、Colorectal Cancer Treatments and Studies、Colorectal Cancer Surgical Treatments